Abatacept Plus Methotrexate Provides Incremental Clinical Benefits Versus Methotrexate Alone in Methotrexate-naive Patients with Early Rheumatoid Arthritis Who Achieve Radiographic Nonprogression

ALVIN F. WELLS, RENE WESTHOVENS, DIANE MONIZ REED, LUCIANA FANTI, JEAN-CLAUDE BECKER, ALLISON COVUCCI and EDWARD C. KEYSTONE

J Rheumatol 2011;38;2362-2368
http://www.jrheum.org/content/38/11/2362

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Abatacept Plus Methotrexate Provides Incremental Clinical Benefits Versus Methotrexate Alone in Methotrexate-naive Patients with Early Rheumatoid Arthritis Who Achieve Radiographic Nonprogression

ALVIN F. WELLS, RENE WESTHOVENS, DIANE MONIZ REED, LUCIANA FANTI, JEAN-CLAUDE BECKER, ALLISON COVUCCI, and EDWARD C. KEYSTONE

ABSTRACT. Objective. This article reports 1-year clinical outcomes in the subgroup of patients with rheumatoid arthritis in the Abatacept study to Gauge Remission and joint damage progression in methotrexate-naive patients with Early Erosive rheumatoid arthritis (AGREE) who achieved radiographic nonprogression at the end of the double-blind phase.

Methods. Patients who achieved radiographic nonprogression (change from baseline in total Sharp score ≤ 0 at 12 months) with abatacept plus methotrexate (MTX) or MTX alone were eligible for this analysis. Clinical outcomes were remission, defined by 28-joint Disease Activity Score (DAS28) using C-reactive protein (CRP), low Disease Activity Score (LDAS), American College of Rheumatology (ACR) scores, physical function (Health Assessment Questionnaire), and tender and swollen joint counts. Safety was assessed at each visit.

Results. Patients in the abatacept plus MTX and MTX monotherapy groups had similar baseline characteristics and were similar to the overall study population. The proportion of patients who achieved DAS28 (CRP) remission or LDAS was greater with abatacept plus MTX vs MTX alone [43.2% vs 22.7% (p < 0.001) and 57.4% vs 40.6% (p = 0.008), respectively]. More patients receiving abatacept plus MTX achieved key ACR responses, including major clinical response (27.3% vs 11.9%; p < 0.001). Safety profiles were similar in both treatment groups.

Conclusion. More MTX-naive patients with early RA who achieved radiographic nonprogression taking abatacept plus MTX also achieved DAS28 (CRP)-defined remission and LDAS compared with patients who received MTX alone, supporting the use of abatacept as a first-line biologic in combination with disease-modifying antirheumatic drugs. (First Release Sept 1 2011; J Rheumatol 2011;38: 2362–8; doi:10.3899/jrheum.110054)

Key Indexing Terms: RHEUMATOID ARTHRITIS CLINICAL OUTCOMES REMISSION RADIOGRAPHIC NONPROGRESSION ABATACEPT METHOTREXATE anticitrullinated protein antibodies (ACPA) type 2, is indicative of a poor prognosis for radiographic damage6,7,8. Further, greater joint damage at baseline is associated with less improvement in physical functioning after treatment, which highlights the importance of early intervention9,10.

Targeted biologic therapies have provided significant benefits compared with traditional RA therapies and represent a...
considerable advancement in the treatment of RA. Increasing evidence from clinical trials in patients with moderate to severe RA suggests that the introduction of biologics in combination with nonbiologics earlier in the course of disease leads to greater clinical benefit in the treatment of early RA. While an association between radiographic damage and loss of physical function over the long term course of RA has been recognized, the relationships among early treatment (particularly in patients with a poor prognosis), radiographic damage, disease activity, and functionality in early disease remain to be established. Data suggest that treatment with a biologic plus methotrexate (MTX) provides greater radiographic inhibition than MTX monotherapy in patients with minimal clinical response, suggesting that clinical measures of RA disease activity and radiographic damage may be dissociated.

Abatacept is a soluble human recombinant fusion protein that blocks the activation of T cells by modulating the CD80/CD86:CD28 costimulatory signal. The sustained clinical and radiographic efficacy of abatacept in clinical trials of patients with moderate to severe RA who have had an inadequate response to MTX or anti-tumor necrosis factor (TNF) agents have been previously reported. Further, based on data from the recent ADJUST trial, Emery, et al concluded that compared with no treatment, abatacept may delay the progression of undifferentiated or very early RA in a subset of patients with poor prognosis.

The Abatacept study to Gauge Remission and joint damage progression in methotrexate-naïve patients with Early Erosive rheumatoid arthritis (AGREE) showed that abatacept plus MTX was more effective than MTX alone in achieving 28-joint Disease Activity Score [DAS28 C-reactive protein (CRP)]-defined remission and inhibiting radiographic progression in an MTX-naïve population with early erosive RA and poor prognostic factors. Studies on populations with early RA have shown that combination therapy with biologics and disease-modifying antirheumatic drugs (DMARD) is better than nonbiologic DMARD monotherapy, and a radiographic component may play a role in efficacy. However, while statistically significant, the clinical significance of radiographic improvements is still unclear.

The AGREE trial provides further opportunity to determine differential or incremental clinical benefits associated with biologic therapy compared with MTX monotherapy among patients with early RA who achieved a similar radiographic outcome.

MATERIALS AND METHODS
This is a posthoc analysis of data from AGREE. AGREE was a multinational randomized double-blind 2-year study examining abatacept plus MTX compared with MTX monotherapy in MTX-naïve patients with early erosive RA and poor prognostic factors. Patients. The study design of AGREE has been described. Patients enrolled in AGREE had disease duration ≤ 2 years, were seropositive for RF and/or ACPA, and had radiographic evidence of bone erosions. Patients were either MTX-naïve at study entry or had previous exposure of ≤ 10 mg/week for 3 weeks but not within 3 months prior to initiation of the study.

Patients were randomized 1:1 to receive abatacept (≥ 10 mg/kg according to weight range) plus MTX or placebo plus MTX for 1 year (Figure 1). Abatacept was administered according to weight range by intravenous infusion on Days 1, 15, and 29, and every 4 weeks thereafter. MTX was initially dosed at 7.5 mg/week and titrated to 20 mg at Week 8, where it was maintained. MTX dose reduction to a minimum of 15 mg/week was permitted in cases of toxicity or intolerability.

Abatacept was administered according to weight range by intravenous infusion on Days 1, 15, and 29, and every 4 weeks thereafter. MTX was initially dosed at 7.5 mg/week and titrated to 20 mg at Week 8, where it was maintained. MTX dose reduction to a minimum of 15 mg/week was permitted in cases of toxicity or intolerability.

Stable, fixed low-dose oral corticosteroids (prednisone ≥ 10 mg or equivalent oral or injectable corticosteroids for at least 3 consecutive days) during any 6-month period were permitted. After 6 months, the addition of 1 nonbiologic DMARD was also allowed. Patients who received at least 1 dose of study medication and achieved radiographic nonprogression, defined as a change from baseline in the Genant-modified total Sharp score (TSS) ≤ 0 at 1 year, were eligible for this posthoc analysis.

Clinical and safety assessments. Clinical and functional endpoints for this analysis included remission, defined as DAS28 (CRP) < 2.6; low Disease Activity Score (LDAS), defined as DAS28 (CRP) ≤ 3.2; American College of Rheumatology (ACR) 50, 70, and 90 responses; major clinical response (MCR; defined as ACR 70 maintained for ≥ 6 consecutive months); physical function assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI); and the number of tender and swollen joints using 68- and 66-joint count assessments, respectively. Safety assessments, including all reported adverse events (AE), serious AE (SAE), and infections, were performed monthly at each scheduled visit and reported for all patients who received at least 1 dose of abatacept.

Statistical analyses. Baseline demographic and disease characteristics were reported using descriptive statistics. Analyses of clinical, functional, and safety responses were performed on patients who achieved radiographic nonprogression using data available at the 1-year visit. ACR response, DAS28 remission, and LDAS were assessed using an intent-to-treat population, with patients who discontinued considered nonresponders subsequent to discontinuation for clinical outcomes. Missing radiographic data at Day 365 for discontinued patients were imputed using linear extrapolation. All other analysis was based on as-observed data. A chi-square test corrected for continuity was used to evaluate differences between treatment groups in DAS28 (CRP), MCR, and ACR responses. All confidence intervals were 2-sided.

RESULTS
Patient disposition and demographics. In the 1-year double-blind portion of AGREE, 509 patients were randomized and treated with abatacept plus MTX or MTX alone. Of the 509 patients, 484 had radiographs collected at baseline and at least 1 post-baseline visit. Sixty-one percent (148 of 242) of patients in the abatacept plus MTX group and 53% (128 of 242) of patients in the MTX monotherapy group achieved radiographic nonprogression at 1 year and thus were eligible for this analysis. Baseline demographics and disease characteristics were similar between both groups of radiographic nonprogressors (Table 1) and were generally similar to those reported for the overall study population. Mean disease duration was 5.9 and 7.0 months for the abatacept plus MTX and MTX monotherapy groups, respectively. Tender and swollen joint counts were similar between the 2 groups. The mean DAS28 (CRP) was 6.2 in both groups, and mean TSS was 6.7 and 5.8 for the abatacept plus MTX and MTX monotherapy groups, respectively.
At 1 year, mean (SD) DAS28 (CRP) was 2.9 ± 1.29 and 3.61 ± 1.29 for radiographic nonprogressors treated with abatacept plus MTX and MTX alone, respectively. Additionally, more abatacept plus MTX nonprogressors achieved DAS28 (CRP)-defined remission compared with nonprogressors treated with MTX alone (43.2% vs 22.7%, respectively; \( p < 0.001 \); Figure 2). A greater proportion of radiographic nonprogressors treated with abatacept plus MTX also achieved LDAS at 1 year compared with those treated with MTX alone (29.1% vs 11.7%, respectively; \( p < 0.001 \); Figure 4).

The proportion of radiographic nonprogressors achieving DAS28 (CRP) remission increased consistently over time (Figure 3A). The same trend was observed for LDAS in radiographic nonprogressors (Figure 3B).

ACR responses. Radiographic nonprogressors treated with abatacept plus MTX achieved ACR 50, 70, and 90 responses at 1 year more than nonprogressors treated with MTX alone (\( p = 0.014 \), \( p = 0.003 \), \( p = 0.004 \), respectively; Figure 4). MCR was achieved in more patients treated with abatacept plus MTX compared with MTX alone (29.1% vs 11.7%, respectively; \( p < 0.001 \); Figure 4).

Functional status. At 1 year, mean HAQ-DI decreases from baseline were similar between the 2 groups of radiographic nonprogressors (–1.0 ± 0.8 vs –0.8 ± 0.7 units for abatacept plus MTX vs MTX alone, respectively). Mean tender joint count at 1 year was 6.9 ± 11.7 for abatacept plus MTX compared with 10.1 ± 11.8 for MTX alone. Mean swollen joint count at 1 year was 3.9 ± 7.3 for abatacept plus MTX compared with 6.1 ± 7.8 for MTX alone.

Safety and tolerability. The type and incidence of AE and SAE were similar between radiographic nonprogressors receiving abatacept plus MTX and those receiving MTX alone (Table 2) and were generally similar to those reported for the overall study population\(^{15}\).

DISCUSSION

The 2010 RA classification criteria issued by the ACR and the European League Against Rheumatism were designed to facilitate the identification of patients with RA earlier during their disease course\(^{34}\). By identifying patients earlier in the disease process, it may be possible to use DMARD therapy earlier in order to ameliorate or prevent the damaging effects of RA\(^{34}\).
In the primary AGREE trial, it was shown that 41.4% of patients treated with a combination of abatacept and MTX achieved clinical remission (DAS28 < 2.6) compared to 23.3% of patients in the group that received MTX alone. Further, 61% of patients treated with abatacept plus MTX achieved radiographic nonprogression (TSS ≤ 0) compared to 53% of patients treated with MTX alone.

The results of these analyses demonstrate for the first time that despite achieving similar radiographic benefit/non-progression, MTX-naive patients with early RA with poor prognostic factors treated with abatacept plus MTX achieved greater clinical benefits than those treated with MTX monotherapy. Baseline demographics and disease characteristics were similar between the 2 groups of radiographic non-progressors. Almost twice as many patients treated with abatacept plus MTX were in clinical remission compared to those receiving MTX alone. Clinical remission was accompanied by improved physical function. In addition, early use of abatacept plus MTX compared with MTX alone resulted in a greater proportion of patients achieving ACR 50, 70, and 90 responses and MCR at 1 year.

The demonstration that only a portion of radiographic non-progressors achieved clinical remission is consistent with the previously described dissociation between clinical and radiographic outcomes in patients treated with biologics or conventional DMARD. Previous studies of combination therapy with TNF inhibitors and MTX in MTX-naive patients with early RA have shown a higher proportion of patients achieving radiographic nonprogression than those achieving clinical remission. This implies that it is more difficult to achieve clinical remission than radiographic non-progression, even with intensive early treatment with biologics. To our knowledge, these are the first data to demonstrate this discordance with a biologic agent other than a TNF antagonist. Whether this dissociation reflects a biologic process or the instruments available to define the clinical states remains unclear.

There are inherent limitations to the posthoc analyses presented on the subgroup of patients with radiographic non-progression. The whole cohort was characterized by radiological nonprogression, to help analyze the differential or incremental clinical benefits offered by combination therapy in these patients. While it is recognized that there has always been variation between the trial setting and the real-world clinical practice setting, these data should be interpreted within the context of this study. While AGREE was not statistically powered to look at outcomes in subgroups, the findings of this posthoc analysis suggest that among MTX-naive patients with early RA in whom radiographic progression is arrested with treatment, there is an incremental clinical benefit when a combination of abatacept plus MTX is used compared with MTX monotherapy. These data further support the early use of intensive combination therapy, such as abatacept and MTX, in patients with early RA, particularly those with features of poor prognosis.

ACKNOWLEDGMENT
The authors thank Nina Leeds, PhD, Sabrina McGuigan, CMPP, and Anu Santhanagopal, PhD, for editorial and submission assistance.
REFERENCES


Table 2. Summary of safety in radiographic nonprogressors during 1 year.

<table>
<thead>
<tr>
<th>Event</th>
<th>No. Patients (%)</th>
<th>Abatacept + MTX (n = 148)</th>
<th>MTX (n = 128)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events (AE)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuations due to AE</td>
<td>130 (88)</td>
<td>114 (89)</td>
<td></td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>76 (51)</td>
<td>82 (64)</td>
<td></td>
</tr>
<tr>
<td>Autoimmune events</td>
<td>5 (3.4)</td>
<td>5 (3.9)</td>
<td></td>
</tr>
<tr>
<td>Serious AE</td>
<td>11 (7.4)</td>
<td>10 (7.8)</td>
<td></td>
</tr>
<tr>
<td>Discontinuations due to serious AE</td>
<td>1 (0.7)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Serious infections and infestations</td>
<td>2 (1.4)</td>
<td>4 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Malignancies</td>
<td>1 (0.7)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>1 (0.7)</td>
<td>2 (1.6)</td>
<td></td>
</tr>
</tbody>
</table>

MTX: methotrexate.


